$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000168316824001818 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$7.541M	$7.680M	$24.09M
YoY Change	54.09%	94.94%	454.42%
Cost Of Revenue	$5.187M	$5.112M	$15.75M
YoY Change	69.17%	108.77%	494.69%
Gross Profit	$2.354M	$2.568M	$8.339M
YoY Change	28.78%	72.22%	391.53%
Gross Profit Margin	31.22%	33.44%	34.61%
Selling, General & Admin	$3.903M	$2.897M	$11.12M
YoY Change	3.12%	-54.06%	-62.02%
% of Gross Profit	165.78%	112.79%	133.34%
Research & Development	$222.0K	$816.3K	$1.856M
YoY Change	-48.71%	1854.81%	128.59%
% of Gross Profit	9.43%	31.79%	22.25%
Depreciation & Amortization	$42.60K	$39.15K	$149.2K
YoY Change	22.73%	106.38%	492.81%
% of Gross Profit	1.81%	1.52%	1.79%
Operating Expenses	$4.125M	$3.755M	$13.12M
YoY Change	-2.2%	-42.47%	-56.38%
Operating Profit	-$1.351M	-$1.187M	-$4.785M
YoY Change	-26.16%	-76.43%	-82.28%
Interest Expense	$49.18K	$157.5K	$674.4K
YoY Change	19.73%	86.12%	1611.2%
% of Operating Profit
Other Income/Expense, Net	$89.14K		$674.4K
YoY Change	-48.42%		37.75%
Pretax Income	-$1.261M	-$1.030M	-$4.111M
YoY Change	-23.83%	-95.58%	-84.49%
Income Tax	$22.35K	$220.3K	$395.2K
% Of Pretax Income
Net Earnings	-$1.284M	-$1.250M	-$4.506M
YoY Change	-24.59%	-94.68%	-83.15%
Net Earnings / Revenue	-17.02%	-16.28%	-18.7%
Basic Earnings Per Share	-$2.00		-$0.19
Diluted Earnings Per Share	-$2.00	-$5.25	-$18.52
COMMON SHARES
Basic Shares Outstanding	99.45M shares	25.68M shares	24.33M shares
Diluted Shares Outstanding	641.3K shares		24.33M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.43M	$16.29M	$16.29M
YoY Change	-9.64%	-25.35%	-25.35%
Cash & Equivalents	$17.43M	$16.29M	$16.29M
Short-Term Investments
Other Short-Term Assets	$871.0K	$310.6K	$310.6K
YoY Change	472.05%	9.44%	9.44%
Inventory	$7.698M	$5.735M	$5.735M
Prepaid Expenses	$871.4K	$310.6K
Receivables	$2.828M	$2.552M	$2.552M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.83M	$24.89M	$24.89M
YoY Change	15.57%	-8.87%	-8.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$401.6K	$1.013M	$1.013M
YoY Change	9.13%	156.86%	-12.3%
Goodwill		$0.00
YoY Change
Intangibles	$2.066M	$1.444M
YoY Change	117.84%	85.91%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.067M	$2.457M	$2.457M
YoY Change	50.04%	27.2%	27.2%
TOTAL ASSETS
Total Short-Term Assets	$28.83M	$24.89M	$24.89M
Total Long-Term Assets	$3.067M	$2.457M	$2.457M
Total Assets	$31.90M	$27.35M	$27.35M
YoY Change	18.18%	-6.49%	-6.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.615M	$2.585M	$2.585M
YoY Change	32.13%	-7.75%	-7.75%
Accrued Expenses	$115.0K	$118.7K	$118.7K
YoY Change	-5.19%	-3.54%	-3.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.533M	$5.552M	$5.552M
YoY Change	-5.39%	-19.9%	-19.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$497.0K	$539.0K	$539.0K
YoY Change	-18.94%	-16.07%	-16.07%
Total Long-Term Liabilities	$545.7K	$539.0K	$539.0K
YoY Change	-16.84%	-21.34%	-16.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.533M	$5.552M	$5.552M
Total Long-Term Liabilities	$545.7K	$539.0K	$539.0K
Total Liabilities	$7.079M	$6.140M	$6.140M
YoY Change	-6.38%	-19.39%	-19.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.19M	-$63.91M
YoY Change	6.69%	7.59%
Common Stock	$995.00	$28.02K
YoY Change	-95.51%	24.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.82M	$21.21M	$21.21M
YoY Change
Total Liabilities & Shareholders Equity	$31.90M	$27.35M	$27.35M
YoY Change	18.18%	-6.49%	-6.49%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.284M	-$1.250M	-$4.506M
YoY Change	-24.59%	-94.68%	-83.15%
Depreciation, Depletion And Amortization	$42.60K	$39.15K	$149.2K
YoY Change	22.73%	106.38%	492.81%
Cash From Operating Activities	-$3.185M	-$2.685M	-$8.775M
YoY Change	72.16%	19.52%	67.2%
INVESTING ACTIVITIES
Capital Expenditures	$699.8K	$308.1K	$788.1K
YoY Change	292.26%	1.02%	306.27%
Acquisitions
YoY Change
Other Investing Activities	$31.10K	$31.95K	$132.0K
YoY Change	-3.09%	-100.22%	-100.92%
Cash From Investing Activities	-$668.7K	-$266.2K	-$656.2K
YoY Change	357.09%	-98.18%	-95.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$537.6K
YoY Change			-101.77%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.398M	-34.41K	3.426M
YoY Change	-1102.82%	-98.36%	-91.32%
NET CHANGE
Cash From Operating Activities	-$3.185M	-2.685M	-8.775M
Cash From Investing Activities	-$668.7K	-266.2K	-656.2K
Cash From Financing Activities	$5.398M	-34.41K	3.426M
Net Change In Cash	$1.544M	-2.986M	-6.006M
YoY Change	-160.92%	-84.25%	-130.65%
FREE CASH FLOW
Cash From Operating Activities	-$3.185M	-$2.685M	-$8.775M
Capital Expenditures	$699.8K	$308.1K	$788.1K
Free Cash Flow	-$3.885M	-$2.993M	-$9.563M
YoY Change	91.52%	17.31%	75.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001402328
CY2022	SBFM	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease		usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41282
CY2023	dei	Entity Registrant Name EntityRegistrantName	SUNSHINE BIOPHARMA, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5566275
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1177 Avenue of the Americas
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	5th Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2023	dei	City Area Code CityAreaCode	(332)
CY2023	dei	Local Phone Number LocalPhoneNumber	216-1147
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	10708072	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99452865	shares
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16292347	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2552362	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1912153	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5734755	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3289945	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	310591	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	283799	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	24890055	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27312334	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	365868	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394249	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1444259	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	776856	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646779	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	760409	usd
CY2023Q4	us-gaap	Assets Assets	27346961	usd
CY2022Q4	us-gaap	Assets Assets	29243848	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2585466	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2802797	usd
CY2023Q4	SBFM	Earnout Payable EarnoutPayable	2547831	usd
CY2022Q4	SBFM	Earnout Payable EarnoutPayable	3632000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	299869	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	373191	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118670	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123026	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5551836	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6931014	usd
CY2023Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	48729	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	539035	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642232	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	587764	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	685264	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6139600	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7616278	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22585632	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22585632	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	28024	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22585	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84387890	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80841752	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	696105	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	161847	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63905658	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59399614	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21207361	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27346961	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29243848	usd
CY2023	us-gaap	Revenues Revenues	24092787	usd
CY2022	us-gaap	Revenues Revenues	4345603	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	463705	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	341139	usd
CY2023	SBFM	Consulting Expense ConsultingExpense	850173	usd
CY2022	SBFM	Consulting Expense ConsultingExpense	842894	usd
CY2023	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	400000	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	300000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18326719	usd
CY2023	us-gaap	Legal Fees LegalFees	512199	usd
CY2022	us-gaap	Legal Fees LegalFees	550117	usd
CY2023	us-gaap	Marketing Expense MarketingExpense	734248	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	578085	usd
CY2023	SBFM	Office Expense OfficeExpense	2142355	usd
CY2022	SBFM	Office Expense OfficeExpense	796007	usd
CY2023	SBFM	Patent Fees PatentFees	14108	usd
CY2022	SBFM	Patent Fees PatentFees	15148	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1855830	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	811858	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	5712968	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	6054962	usd
CY2023	SBFM	Taxes Taxes	289737	usd
CY2022	SBFM	Taxes Taxes	55233	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	149147	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25163	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13124470	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28697325	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4785299	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-27000750	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-245	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-476	usd
CY2023	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	811974	usd
CY2022	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	518650	usd
CY2023	us-gaap	Interest Expense InterestExpense	137308	usd
CY2022	us-gaap	Interest Expense InterestExpense	39412	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	674421	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	489614	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4110878	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26511136	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	395166	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	233304	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4506044	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26744440	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	534258	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	184986	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3971786	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26559454	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.76
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.76
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24331908	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24331908	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15180868	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15180868	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4506044	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26744440	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	149147	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25163	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18326719	usd
CY2023	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-0	usd
CY2022	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-548	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	594141	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	524486	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2365549	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-42983	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	21143	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-82846	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1364134	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3359141	usd
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	3628	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-73247	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	238679	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-48287	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8775111	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5248358	usd
CY2023	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	131949	usd
CY2022	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	33379	usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	-0	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	14346637	usd
CY2023	SBFM	Cash From Nora Pharma Acquisition CashFromNoraPharmaAcquisition	-0	usd
CY2022	SBFM	Cash From Nora Pharma Acquisition CashFromNoraPharmaAcquisition	1135	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	705848	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	111015	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82251	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	193982	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-656150	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14619390	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4089218	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30367185	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3502	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13193177	usd
CY2023	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	541143	usd
CY2022	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	99000	usd
CY2023	SBFM	Payment For Lease Liability PaymentForLeaseLiability	125990	usd
CY2022	SBFM	Payment For Lease Liability PaymentForLeaseLiability	31924	usd
CY2023	SBFM	Advances To Nora Pharma Pre Acquisitio AdvancesToNoraPharmaPreAcquisitio	-0	usd
CY2022	SBFM	Advances To Nora Pharma Pre Acquisitio AdvancesToNoraPharmaPreAcquisitio	2064331	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1900000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3425587	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39465107	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2045167	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6005674	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	19597359	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-62674	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1075	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	534258	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	184986	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16292347	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	48287	usd
CY2023	SBFM	Stock Issued For Acquisition Of Norma Pharma StockIssuedForAcquisitionOfNormaPharma	0	usd
CY2022	SBFM	Stock Issued For Acquisition Of Norma Pharma StockIssuedForAcquisitionOfNormaPharma	4514000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
CY2022	SBFM	Common Stock And Prefunded Warrants Issued In Public And Private Offerings Net Of Issuance Costs CommonStockAndPrefundedWarrantsIssuedInPublicAndPrivateOfferingsNetOfIssuanceCosts	30367185	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13193177	usd
CY2022	SBFM	Preferred Stock Purchased From Related Party PreferredStockPurchasedFromRelatedParty	-99000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4514000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26559454	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	541143	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4089218	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3502	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3971786	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21207361	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zAWnXusq7tul" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zNhIdI5J17ph">USE OF ESTIMATES</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z2rfVTEl0q4b" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(0,72,127); text-align: justify"><i><span id="xdx_86B_zxzJlioUWff6">CONCENTRATION OF CREDIT RISKS</span></i></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	18326719	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18326719	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	0	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	659571	usd
CY2022	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	121807	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	781378	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4522	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	776856	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	776856	usd
CY2023	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	710372	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1487228	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	42969	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1444259	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	59745	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	59745	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	58541	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	19041	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	9985	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	555864	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	478055	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	189996	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	83806	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	365868	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394249	usd
CY2023	us-gaap	Depreciation Depreciation	110701	usd
CY2022	us-gaap	Depreciation Depreciation	20641	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000	usd
CY2023	us-gaap	Dividends Dividends	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4506044	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26744440	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24331908	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15180868	shares
CY2023	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2022	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24331908	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15180868	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.76
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	50	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	379246	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	15870	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	395166	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-826953	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2014	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	50	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0000	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	56812	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0138	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	860705	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2096	pure
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	167676	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0408	pure
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	67144	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.0163	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	69732	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0170	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	395166	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0962	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5277829	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	641800	usd
CY2023Q4	SBFM	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	25327	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	454890	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	174292	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6397374	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	176764	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	54095	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	171396	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	225491	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	48727	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646779	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118670	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	539035	usd
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118670	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	118862	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	112582	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	106042	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	99881	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	101667	usd
CY2023	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1515000	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1785000	usd
CY2023	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	400000	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	300000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-001818-index-headers.html	Edgar Link	pending
0001683168-24-001818-index.html	Edgar Link	pending
0001683168-24-001818.txt	Edgar Link	pending
0001683168-24-001818-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbfm-20231231.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
sunshine_ex2101.htm	Edgar Link	pending
sunshine_ex2301.htm	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sbfm-20231231_def.xml	Edgar Link	unprocessable
sbfm-20231231_pre.xml	Edgar Link	unprocessable
sbfm-20231231_lab.xml	Edgar Link	unprocessable
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_ex9701.htm	Edgar Link	pending
sunshine_i10k-123123.htm	Edgar Link	pending
sbfm-20231231_cal.xml	Edgar Link	unprocessable
sunshine_i10k-123123_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2024 Q1 Form 10-K Financial Statement

#000168316824001818 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2024 Q1 Form 10-K Financial Statement

#000168316824001818 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm